Search research articles
Contact Us
Filters
Showing results (21-30 of 32) with videos related to
Page
of 4
Sort By:
Annals of Hematology
|
January 19, 2022
Identification of CD105 (endoglin) as novel risk marker in CLL
Sarah M Greiner, Melanie Märklin, Samuel Holzmayer, et al.
Cancers
|
August 26, 2022
IgG-Based Bispecific Anti-CD95 Antibodies for the Treatment of B Cell-Derived Malignancies and Autoimmune Diseases
Sebastian Hörner, Moustafa Moustafa-Oglou, Karin Teppert, et al.
Blood Advances
|
June 12, 2026
High-risk single-refractory and double-refractory chronic lymphocytic leukemia: feasibility and impact of alloHCT
Joseph Kauer, Isabelle Krämer, Patrick Derigs, et al.
Cancers
|
March 10, 2022
Prolonged Exposure to Oxaliplatin during HIPEC Improves Effectiveness in a Preclinical Micrometastasis Model
Nick Seyfried, Can Yurttas, Markus Burkard, et al.
Journal for Immunotherapy of Cancer
|
March 15, 2022
A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL
Naveen K Mehta, Martin Pfluegler, Kristan Meetze, et al.
Blood Advances
|
September 18, 2024
Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML
Julia M Unglaub, Richard F Schlenk, Jan Moritz Middeke, et al.
EMBO Molecular Medicine
|
December 29, 2020
An IgG-based bispecific antibody for improved dual targeting in PSMA-positive cancer
Latifa Zekri, Fabian Vogt, Lukas Osburg, et al.
Journal for Immunotherapy of Cancer
|
October 8, 2024
EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma
Jan H Frenking, Xiang Zhou, Vivien Wagner, et al.
Blood Advances
|
April 23, 2025
Bridging intensity is associated with impaired hematopoietic recovery following BCMA CAR-T therapy for multiple myeloma
Jan Hendrik Frenking, Xiang Zhou, Kai Rejeski, et al.
Blood Advances
|
December 11, 2024
Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World Study
Evgenii Shumilov, Rebecca Wurm-Kuczera, Andrea Kerkhoff, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 32) with videos related to
Sort By:
Page
of 4
Annals of Hematology
|
January 19, 2022
Identification of CD105 (endoglin) as novel risk marker in CLL
Sarah M Greiner, Melanie Märklin, Samuel Holzmayer, et al.
Cancers
|
August 26, 2022
IgG-Based Bispecific Anti-CD95 Antibodies for the Treatment of B Cell-Derived Malignancies and Autoimmune Diseases
Sebastian Hörner, Moustafa Moustafa-Oglou, Karin Teppert, et al.
Blood Advances
|
June 12, 2026
High-risk single-refractory and double-refractory chronic lymphocytic leukemia: feasibility and impact of alloHCT
Joseph Kauer, Isabelle Krämer, Patrick Derigs, et al.
Cancers
|
March 10, 2022
Prolonged Exposure to Oxaliplatin during HIPEC Improves Effectiveness in a Preclinical Micrometastasis Model
Nick Seyfried, Can Yurttas, Markus Burkard, et al.
Journal for Immunotherapy of Cancer
|
March 15, 2022
A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL
Naveen K Mehta, Martin Pfluegler, Kristan Meetze, et al.
Blood Advances
|
September 18, 2024
Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML
Julia M Unglaub, Richard F Schlenk, Jan Moritz Middeke, et al.
EMBO Molecular Medicine
|
December 29, 2020
An IgG-based bispecific antibody for improved dual targeting in PSMA-positive cancer
Latifa Zekri, Fabian Vogt, Lukas Osburg, et al.
Journal for Immunotherapy of Cancer
|
October 8, 2024
EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma
Jan H Frenking, Xiang Zhou, Vivien Wagner, et al.
Blood Advances
|
April 23, 2025
Bridging intensity is associated with impaired hematopoietic recovery following BCMA CAR-T therapy for multiple myeloma
Jan Hendrik Frenking, Xiang Zhou, Kai Rejeski, et al.
Blood Advances
|
December 11, 2024
Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World Study
Evgenii Shumilov, Rebecca Wurm-Kuczera, Andrea Kerkhoff, et al.
Page
of 4